Kisplyx (lenvatinib), in combination with everolimus, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor targeted therapy. The opinion was based on results from a phase II trial that showed...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
